In this episode, Christopher Koddermann interviews Dr. Sam Banister: co-founder and chief scientific officer of Psylo, an Australian biotech company developing next-generation psychedelics. Banister discusses how he got involved in drug development, how Psylo came about, and the hallucinogenic and non-hallucinogenic 5-HT2A agonists Psylo is working on. He talks about the compromise between immediate need and ambition, and the ethical considerations and possibilities behind developing non-hallucinogenic compounds: What can we take from the psychedelic experience for people who aren’t ideal candidates for one? Is the psychedelic experience truly necessary? And for what indications will these new Gen 3 compounds be most useful? He discusses:  What we can infer about the volatility of biotech and the state of the psychedelic industry based on recent mergers and acquisitions The long-term challenges of drug development and the scalability of treatment options How the initial success of Spravato has played a role in allaying fears around new compounds Head twitch response and concerns it’s not as accurate of a metric as we’ve believed Australia’s decision to down-schedule psilocybin and MDMA, and the speed of implementation and licensing: How long will it be before people have easy access? What he sees for the future and why we need to be careful with language around expectations  and more!  Click here to head to teh show notes page. 

PT491 – Dr. Sam Banister – Drug Development, The State of Biotech, and Exploring Non-Hallucinogenic Compounds

Get Started

Download the App